COMBINATION OF SORAFENIB AND 5-AZACYTIDINE HAS SIGNIFICANT ACTIVITY IN PATIENTS WITH RELAPSED/REFRACTORY OR UNTREATED ACUTE MYELOID LEUKEMIA AND FLT3-ITD MUTATION

被引：0
|
作者：
Ravandi, Farhad [1 ]
Alattar, Mona Lisa [1 ]
Levis, Mark [1 ]
Garcia-Manero, Guillermo [1 ]
Richie, Mary A. [1 ]
Daver, Naval [1 ]
Faderl, Stefan [1 ]
Borthakur, Gautam [1 ]
Burger, Jan [1 ]
Kadia, Tapan [1 ]
Grunwald, Michael [1 ]
Dellasala, Sara [1 ]
Cortes, Jorge [1 ]
Kantarjian, Hagop [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
ANNALS OF HEMATOLOGY | 2013年 / 92卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
45
引用
收藏
页码：S19 / S20
页数：2
相关论文
共 50 条
  • [1] Combination of Sorafenib and 5-Azacytidine Has Significant Activity in Patients with Relapsed/Refractory or Untreated Acute Myeloid Leukemia and FLT3-ITD mutation
    Ravandi, Farhad
    Alattar, Mona Lisa
    Levis, Mark J.
    Garcia-Manero, Guillermo
    Richie, Mary A.
    Daver, Naval G.
    Faderl, Stefan
    Andreeff, Michael
    Borthakur, Gautam
    Burger, Jan A.
    Kadia, Tapan M.
    Grunwald, Michael R.
    Dellasala, Sara E.
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    BLOOD, 2012, 120 (21)
  • [2] Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia
    Ohanian, Maro
    Garcia-Manero, Guillermo
    Levis, Mark
    Jabbour, Elias
    Daver, Naval
    Borthakur, Gautam
    Kadia, Tapan
    Pierce, Sherry
    Burger, Jan
    Richie, Mary Ann
    Pater, Keyur
    Andreeff, Michael
    Estrov, Zeev
    Cortes, Jorge
    Kantarjian, Hagop
    Ravandi, Farhad
    AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (09) : 1136 - 1141
  • [3] PHASE II STUDY OF SORAFENIB AND 5-AZACYTIDINE (AZA) IN PATIENTS WITH RELAPSED, REFRACTORY OR UNTREATED AML AND FLT3-ITD MUTATION
    Ravandi, Farhad
    Alattar, Mona Lisa
    Levis, Mark
    Faderl, Stefan
    Burger, Jan
    Grunwald, Michael
    Cortes, Jorge
    Kantarjian, Hagop
    ANNALS OF HEMATOLOGY, 2013, 92 : S16 - S16
  • [4] FINAL REPORT OF PHASE II TRIAL OF COMBINATION OF SORAFENIB AND 5-AZACYTIDINE IN PATIENTS WITH FLT3-ITD POSITIVE ACUTE MYELOID LEUKEMIA
    Ravandi, F.
    Levis, M.
    Faderl, S.
    Garcia-Manero, G.
    Cortes, J.
    Kantarjian, H.
    HAEMATOLOGICA, 2013, 98 : 248 - 248
  • [5] Combination of Sorafenib and 5-Azacytidine in Older Patients with Untreated Acute Myeloid Leukemia with FLT3-ITDmutation
    Ohanian, Maro
    Garcia-Manero, Guillermo
    Jabbour, Elias J.
    Daver, Naval
    Borthakur, Gautam
    Kadia, Tapan M.
    Brandt, Mark
    Pierce, Sherry
    Burger, Jan
    Richie, Mary Ann
    Patel, Keyur
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    Ravandi, Farhad
    BLOOD, 2016, 128 (22)
  • [6] Compassionate Use of Sorafenib in Relapsed and Refractory Flt3-ITD Positive Acute Myeloid Leukemia
    Metzelder, Stephan
    Scholl, Sebastian
    Matthias, Kroeger
    Reiter, Andreas
    Meyer, Ralf G.
    Heinicke, Thomas
    Giagounidis, Aristoteles
    Wolfgang, Brugger
    Voehringer, Mathias
    Stadler, Michael
    Schultheis, Beate
    Mueller, Lothar
    Haenel, Mathias
    Hochhaus, Andreas
    Enghofer, Erich
    Neubauer, Andreas
    Burchert, Andreas
    BLOOD, 2009, 114 (22) : 813 - 814
  • [7] Response rates in patients with relapsed/refractory acute myeloid leukemia with FLT3-ITD mutation using 5-azacitadine plus sorafenib
    Alattar, Mona Lisa
    Kantarjian, Hagop
    Levis, Mark J.
    Richie, Mary Ann
    Daver, Naval Guastad
    Garcia-Manero, Guillermo
    Faderl, Stefan
    Borthakur, Gautam
    Burger, Jan Andreas
    Kadia, Tapan M.
    Grunwald, Michael Richard
    Dellasala, Sara
    Cortes, Jorge E.
    Ravandi, Farhad
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (30)
  • [8] Sorafenib in relapsed and refractory FLT3-ITD positive acute myeloid leukemia: a novel treatment option
    Metzelder, S. K.
    Wollmer, E.
    Neubauer, A.
    Burchert, A.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2010, 135 (38) : 1852 - 1856
  • [9] Sorafenib plus 5-azacytidine (AZA) in older untreated FLT3-ITD mutated AML.
    Ohanian, Maro
    Garcia-Manero, Guillermo
    Levis, Mark J.
    Jabbour, Elias
    Daver, Naval Guastad
    Borthakur, Gautam
    Kadia, Tapan M.
    Brandt, Mark
    Pierce, Sherry
    Burger, Jan Andreas
    Richie, Mary Ann
    Patel, Keyur
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    Ravandi, Farhad
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] Sorafenib in combination with intensive chemotherapy for relapsed or refractory FLT3-ITD positive acute myeloid leukemia: A two centers experience
    Urbino, Irene
    Secreto, Carolina
    Apolito, Vincenzo
    Olivi, Matteo
    Arrigo, Giulia
    Boscaro, Eleonora
    Catania, Federica Maria
    D'Ardia, Stefano
    Frairia, Chiara
    Giai, Valentina
    Freilone, Roberto
    Bruno, Benedetto
    Lanzarone, Giuseppe
    Giaccone, Luisa
    Busca, Alessandro
    Dellacasa, Chiara Maria
    Ferrero, Dario
    Audisio, Ernesta
    Cerrano, Marco
    LEUKEMIA RESEARCH, 2024, 136
12345